$8.71
1.69% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
CA05156V1022
Symbol
AUPH
Sector
Industry

Aurinia Pharmaceuticals Inc. Stock price

$8.71
+1.66 23.55% 1M
+3.50 67.18% 6M
-0.28 3.11% YTD
+0.17 1.99% 1Y
-11.00 55.81% 3Y
+2.52 40.71% 5Y
+4.90 128.61% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
-0.15 1.69%
ISIN
CA05156V1022
Symbol
AUPH
Sector
Industry

Key metrics

Market capitalization $1.25b
Enterprise Value $986.19m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 34.29
EV/Sales (TTM) EV/Sales 4.48
P/S ratio (TTM) P/S ratio 5.66
P/B ratio (TTM) P/B ratio 3.21
Revenue growth (TTM) Revenue growth 38.72%
Revenue (TTM) Revenue $220.36m
EBIT (operating result TTM) EBIT $-15.70m
Free Cash Flow (TTM) Free Cash Flow $28.76m
Cash position $348.75m
EPS (TTM) EPS $-0.16
P/E forward negative
P/S forward 5.29
EV/Sales forward 4.19
Short interest 5.16%
Show more

Is Aurinia Pharmaceuticals Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Aurinia Pharmaceuticals Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Aurinia Pharmaceuticals Inc. forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Aurinia Pharmaceuticals Inc. forecast:

Buy
86%
Hold
14%

Financial data from Aurinia Pharmaceuticals Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
220 220
39% 39%
100%
- Direct Costs 28 28
159% 159%
13%
192 192
30% 30%
87%
- Selling and Administrative Expenses 166 166
10% 10%
75%
- Research and Development Expense 23 23
54% 54%
10%
3.83 3.83
104% 104%
2%
- Depreciation and Amortization 20 20
175% 175%
9%
EBIT (Operating Income) EBIT -16 -16
83% 83%
-7%
Net Profit -23 -23
71% 71%
-10%

In millions USD.

Don't miss a Thing! We will send you all news about Aurinia Pharmaceuticals Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aurinia Pharmaceuticals Inc. Stock News

Neutral
Business Wire
8 days ago
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis.
Neutral
Business Wire
11 days ago
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), announced today the acceptance of four poster presentations at the annual American College of Rheumatology Convergence (ACR) 2024 taking place in Washington, D.C., November 14-19. The data highlight the need for additional screening for lupus nephritis (LN), a serious manif...
Neutral
Business Wire
12 days ago
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia to Participate in Jefferies London Healthcare Conference.
More Aurinia Pharmaceuticals Inc. News

Company Profile

Aurinia Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of a therapeutic drug to treat autoimmune diseases. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.

Head office Canada
CEO Peter Greenleaf
Employees 300
Founded 1993
Website www.auriniapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today